|5.||Hypotension (Low Blood Pressure)
|1.||Zeymer, Uwe: 19 articles (10/2015 - 07/2003)|
|2.||Werdan, Karl: 17 articles (07/2015 - 10/2004)|
|3.||Thiele, Holger: 15 articles (10/2015 - 07/2005)|
|4.||Hochman, Judith S: 14 articles (02/2014 - 08/2003)|
|5.||Böhm, Michael: 11 articles (10/2015 - 08/2007)|
|6.||Schuler, Gerhard: 11 articles (08/2015 - 07/2005)|
|7.||Prondzinsky, Roland: 11 articles (01/2015 - 05/2007)|
|8.||Tsai, Feng-Chun: 11 articles (11/2014 - 03/2006)|
|9.||Waksman, Ron: 11 articles (07/2014 - 09/2006)|
|10.||Yip, Hon-Kan: 11 articles (01/2013 - 09/2002)|
03/22/2006 - "Levosimendan causes rapid improvement in hemodynamic function in patients with cardiogenic shock. "
12/15/2004 - "If the promising results of smaller studies (LIDO, RUSSLAN) with respect to the mortality of the treated patients can be supported by a larger, already initiated study (SURVIVE), levosimendan would be a valuable alternative and/or addition to the conventional therapy of cardiogenic shock."
08/18/2008 - "Levosimendan seems to be effective in improving the Doppler echocardiographic parameters of LV diastolic function in patients with STEMI revascularised by primary PCI who developed cardiogenic shock."
01/01/2010 - "Efficacy of levosimendan in Takotsubo-related cardiogenic shock."
12/01/2013 - "The author, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses of these papers are shown in table 1. The clinical bottom line is that there is no evidence that levosimendan improves outcome in cardiogenic shock. "
|2.||Dopamine (Intropin)FDA LinkGeneric
06/01/1981 - "Maximum dopamine doses (10 microgram/kg/min and more) were effective in the areactive form of cardiogenic shock. "
06/24/1985 - "[Dopamine treatment in cardiogenic shock]."
10/05/1979 - "[Dopamine in cardiogenic shock]."
07/15/1977 - "The effect of dopamine was tested in 20 patients with cardiogenic shock. "
07/15/1977 - "[Dopamine in patients with cardiogenic shock (author's transl)]."
01/01/1992 - "Enoximone thus improved hemodynamic performance significantly in cardiogenic shock after open-heart surgery. "
03/01/1994 - "Enoximone proved to be safe and effective in the treatment of cardiogenic shock. "
01/01/1992 - "Efficacy of phosphodiesterase inhibitor enoximone in management of postcardiotomy cardiogenic shock."
07/01/1990 - "In one study of 13 patients in cardiogenic shock already receiving adrenergic support, enoximone was administered as a bolus of 0.5 mg/kg over 20 minutes. "
09/01/2013 - "At multivariable analysis age (OR2.75, p=0.0004), diabetes (OR1.82, p=0.006), preoperative GFR (OR3.81, p<0.0001), preoperative cardiogenic shock (OR1.65, p=0.004), previous cardiac surgery (OR2.12, p=0.0002), type of intervention (OR1.96, p=0.005), and enoximone (OR0.38, p=0.001) were found to be independently associated with postoperative RF. "
|4.||Norepinephrine (Noradrenaline)FDA LinkGeneric
04/01/2014 - "In conclusion, a short-term increase in MAP with norepinephrine in resuscitated cardiogenic shock complicated by postreperfusion disease is associated with better cardiac performance and improved microcirculatory variables."
04/01/2014 - "There are very few data regarding the effects of norepinephrine uptitration on global and regional hemodynamics in cardiogenic shock. "
01/01/2010 - "Our data suggest that short-term norepinephrine dose up-titration in cardiogenic shock patients treated or pretreated with inotropes was tolerated well by the diseased heart."
01/01/2010 - "Our aim was to assess the effects of norepinephrine dose titration on global hemodynamics in cardiogenic shock. "
01/01/2010 - "The effects of short-term norepinephrine up-titration on hemodynamics in cardiogenic shock."
|5.||Nitric Oxide Synthase (NO Synthase)IBA
07/01/2003 - "The results of the present study further support our previous observation that NO synthase inhibitors are beneficial in the treatment of patients with refractory cardiogenic shock."
01/01/2007 - "This definitive trial gave strong indications for stopping any further trial using non-specific inhibitors of nitric oxide synthase in cardiogenic shock and possibly also in any other cardiovascular area."
03/01/2008 - "Nitric oxide synthase inhibitors in cardiogenic shock: present and future."
04/18/2007 - "Lack of benefit from nitric oxide synthase inhibition in patients with cardiogenic shock: looking for the reasons."
02/01/2006 - "Newer therapeutic strategies, including C5 inhibitors and nitric oxide synthase inhibitors, are being combined with traditional strategies, such as inotropic agents, vasopressors, and circulatory assist, to treat cardiogenic shock."
|6.||Lactic AcidFDA LinkGeneric
10/01/2007 - "In a randomized comparison between the TandemHeart and intraaortic balloon pump support in patients with cardiogenic shock, the improved cardiac index afforded by the left ventricular assist device resulted in a more rapid decrease in serum lactate and improved renal function. "
01/01/2013 - "We hypothesized that septic and cardiogenic shock have different effects on hepatosplanchnic lactate exchange and its contribution to hyperlactatemia. "
01/01/2011 - "That lactate value therefore identified high-risk patients as a complication, often with clinical signs of cardiogenic shock of corresponding severities."
10/01/2005 - "In patients suffering from septic or cardiogenic shock, hyperlactatemia was mainly related to increased production, whereas lactate clearance was similar to healthy subjects. "
10/01/2005 - "Lactate clearance, computed using pharmacokinetic calculations, was similar in septic, cardiogenic shock, and controls, respectively: 10.8 +/- 5.4, 9.6 +/- 2.1, and 12.0 +/- 2.6 mL/kg/min. Endogenous lactate production was determined as the initial lactate concentration multiplied by lactate clearance. "
|7.||abciximab (ReoPro)FDA Link
01/01/2013 - "The present study was a retrospective subanalysis of the multicentre randomized Routine Upfront Abciximab Versus Standard Peri-Procedural Therapy in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock (PRAGUE-7) study, which included 80 MI patients in CS undergoing primary percutaneous coronary intervention (PCI). "
01/01/2013 - "Routine pretreatment with abciximab versus standard periprocedural therapy in mechanically ventilated cardiogenic shock patients undergoing primary percutaneous coronary intervention: Subanalysis of the PRAGUE-7 study."
09/01/2011 - "This study did not show any benefit from routine pre-procedural abciximab when compared with a selective abciximab use during the intervention in patients with cardiogenic shock undergoing primary PCI. "
09/01/2011 - "This multicentre open trial randomized 80 patients with AMI complicated by cardiogenic shock expected to undergo primary PCI into group A (routine upfront-pre-procedural-abciximab bolus followed by 12-h abciximab infusion) and group B (standard therapy). "
09/01/2011 - "The aim of this study was to analyse, whether upfront abciximab administration could improve the outcomes of cardiogenic shock. "
06/01/2015 - "The hemodynamic management in cardiogenic shock occurs after moderate volume administration with dobutamine to increase inotropy. "
07/01/2013 - "Dobutamine induced cardiogenic shock due to systolic anterior motion after mitral valve repair."
01/01/2013 - "Her hospital course was complicated by cardiogenic shock that required hemodynamic support with an intra-aortic balloon pump and dobutamine. "
04/01/2012 - "Among drugs proposed in order to manage patients with cardiogenic shock, dobutamine was chosen as the first choice agent in 62% of the cases. "
05/01/2004 - "Dobutamine was chosen for patients with cardiogenic shock by 90% of the respondents. "
06/01/1990 - "When cardiogenic shock responds to treatment, large increases in DO2 lead to small increases in VO2 but large increases in mixed venous oxygen saturation, reflecting improved tissue oxygen availability."
07/01/1997 - "The purpose of this study was to evaluate the change of regional cerebral oxygen saturation (rSO2) during percutaneous cardiopulmonary support (PCPS) in patients with cardiogenic shock. "
10/01/2013 - "The ultimate goal of therapy for cardiogenic shock is to restore microcirculatory function and thereby restore the oxygen supply to sustain cellular function. "
01/01/2010 - "The automation of a portable extracorporeal support system may greatly help people who suffer from cardiogenic shock by providing them with an optimal oxygen perfusion and avoid mult-organ failure while being transported to a hospital. "
07/01/1997 - "Fifteen patients with cardiogenic shock were evaluated during PCPS by continuous monitoring of rSO2, systemic venous oxygen saturation (Svo2), and hemodynamics. "
|10.||Glucagon (Glukagon)FDA Link
11/01/1999 - "[Role of glucagon in toxic cardiogenic shock]."
10/01/1972 - "Glucagon in cardiogenic shock."
05/01/1971 - "[Glucagon in cardiogenic shock]."
12/12/1970 - "[Glucagon and cardiogenic shock]."
01/01/2014 - "In this case report, we describe a 51-year-old patient with a glucagon-producing NET of the pancreas who developed acute heart failure and even cardiogenic shock despite therapy. "
|1.||Extracorporeal Membrane Oxygenation (ECMO)
01/01/2015 - "We report the case of a young female with medication--induced TTC, who presented with cardiogenic shock as initial manifestation, treated successfully with extracorporeal membrane oxygenation (ECMO). "
02/01/2005 - "When LVFWR presents acutely with tamponade and cardiogenic shock in emergency department, salvage with a good outcome is still possible by timely pericardiocentesis and extracorporeal membrane oxygenation (ECMO) support. "
01/01/2013 - "Levitronix CentriMag in ECMO configuration proved to be effective in managing postcardiotomy cardiogenic shock and the results are encouraging. "
02/01/2015 - "In this swine model of acute cardiogenic shock, VA-ECMO improved coronary blood flow and provided some degree of left ventricular unloading for the short duration of the study. "
10/01/2015 - " of cardiogenic shock were gradually improved after ECMO treatment. "
|2.||Counterpulsation (External Counterpulsation)
01/01/1977 - "Are intra-aortic ballon pumping and external counterpulsation effective in the treatment of cardiogenic shock?"
09/01/2009 - "Studies have compared safety and efficacy of percutaneous left ventricular assist devices (LVADs) with intra-aortic balloon pump (IABP) counterpulsation in patients with cardiogenic shock. "
05/01/1996 - "Previous studies have suggested an improved clinical outcome when percutaneous cardiopulmonary support is combined with intraaortic balloon counterpulsation in patients with cardiogenic shock. "
05/29/1998 - "Intraaortic balloon counterpulsation provides temporary hemodynamic and clinical improvement in the majority of patients with cardiogenic shock. "
06/01/1997 - "Thrombolysis plus aortic counterpulsation: improved survival in patients who present to community hospitals with cardiogenic shock."
|3.||Intra-Aortic Balloon Pumping
02/18/1979 - "Early intra-aortic balloon pumping (IABP) and surgery is much more effective in patients with cardiogenic shock secondary to mechanical complications. "
06/01/2004 - "We have reported that percutaneous cardiopulmonary assist systems (PCPS) are effective in treating life-threatening cardiogenic shock that is intractable to treatment with intraaortic balloon pumping (IABP). "
09/01/2006 - "A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock."
10/01/1996 - "Experimental and clinical data indicate that the effectiveness of intraaortic balloon pumping in severe cardiogenic shock may be improved by increasing the volume of the balloon (i.e., until it fully occupies the aorta)."
04/01/2003 - "This animal study was designed to describe the hemodynamic effect of intra-aortic balloon pumping during cardiogenic shock induced by acute MR. "
05/01/2009 - "Many studies confirm that thrombolytic therapy leads to rapid improvement in hemodynamic aberrations associated with PE, and this approach to massive PE with cardiogenic shock is a guideline-based practice. "
12/01/2009 - "Early reperfusion therapy was associated with a significant reduction of hospital mortality in female patients with STEMI complicated by cardiogenic shock (OR 0.68, 95% CI 0.52-0.90) with primary PCI being more effective than thrombolytic therapy (OR 0.46, 95% CI 0.31-0.68). "
01/01/2004 - "This study aimed to compare the outcome of patients with anterior wall MI, without cardiogenic shock on admission, treated with primary PCI or thrombolytic therapy, in everyday practice. "
03/01/2000 - "The results of small studies suggest that thrombolytic therapy might have an impact on survival in massive PE with cardiogenic shock; however, no large studies to further this notion exist. "
08/01/2014 - "This applies to recommendations for reperfusion therapy >12 hours after symptom onset, immediate transfer of all patients after fibrinolytic therapy, rescue PCI for patients with failed fibrinolysis, and intra-aortic balloon pump use in patients with cardiogenic shock. "
|5.||Angioplasty (Angioplasty, Transluminal)
06/01/2000 - "Primary angioplasty expands the reperfusion population by including many patients ineligible for thrombolysis and is more effective for treating patients at high risk, such as those with cardiogenic shock. "
01/01/2000 - "These data indicate that when reperfusion occurs before primary angioplasty, outcomes are strikingly better with less cardiogenic shock, improved procedural outcomes, smaller infarct size, better preservation of left ventricular function, and reduced mortality. "
07/01/2008 - "Data from randomised trials comparing angioplasty with fibrinolysis on the development of cardiogenic shock are lacking. "
05/01/2007 - "Trials of rescue angioplasty (rPCI) following failed fibrinolysis have excluded patients with cardiogenic shock and the benefit of rPCI in this setting is unknown. "
01/01/2007 - "The aim of the study was to evaluate the outcomes of angioplasty and stenting in patients with cardiogenic shock caused by left main coronary artery (LMCA) disease. "